Q1 Earnings Estimate for AVDL Issued By Lifesci Capital

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Avadel Pharmaceuticals in a note issued to investors on Monday, March 3rd. Lifesci Capital analyst M. Belghiti anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

Several other research firms have also weighed in on AVDL. UBS Group dropped their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a report on Monday. Finally, Piper Sandler reduced their target price on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Stock Performance

Avadel Pharmaceuticals stock opened at $7.88 on Wednesday. The company has a 50 day moving average price of $8.67 and a 200 day moving average price of $11.45. Avadel Pharmaceuticals has a 52 week low of $7.39 and a 52 week high of $19.09. The firm has a market capitalization of $759.33 million, a price-to-earnings ratio of -9.97 and a beta of 1.28.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Two Seas Capital LP boosted its stake in shares of Avadel Pharmaceuticals by 90.6% in the 4th quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock valued at $45,156,000 after purchasing an additional 2,042,669 shares during the last quarter. Brandes Investment Partners LP grew its position in shares of Avadel Pharmaceuticals by 58.1% during the 4th quarter. Brandes Investment Partners LP now owns 2,173,139 shares of the company’s stock worth $22,840,000 after buying an additional 798,415 shares during the period. Janus Henderson Group PLC boosted its stake in Avadel Pharmaceuticals by 5.7% during the 4th quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock worth $148,117,000 after acquiring an additional 753,332 shares during the last quarter. Braidwell LP raised its holdings in Avadel Pharmaceuticals by 21.2% in the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock worth $43,151,000 after purchasing an additional 716,787 shares during the period. Finally, State Street Corp grew its holdings in shares of Avadel Pharmaceuticals by 42.5% in the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company’s stock valued at $21,290,000 after buying an additional 483,787 shares during the period. Institutional investors and hedge funds own 69.19% of the company’s stock.

Insider Buying and Selling at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, Director Linda Palczuk purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was acquired at an average cost of $7.93 per share, with a total value of $39,650.00. Following the completion of the acquisition, the director now directly owns 67,900 shares of the company’s stock, valued at $538,447. This represents a 7.95 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Geoffrey Michael Glass bought 20,279 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of $9.84 per share, with a total value of $199,545.36. Following the completion of the purchase, the director now owns 75,904 shares of the company’s stock, valued at approximately $746,895.36. The trade was a 36.46 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 42,981 shares of company stock worth $400,005 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.